Schering Plough news from FierceBiotech
NewsC&L: Somnus names executive team
Gary Cupit, PharmD, has been named CEO of Somnus Therapeutics. The rest of the executive team: Mary Osbakken, MD, PhD, chief medical officer; Christine Blumhardt, PharmD, chief regulatory officer; Read more...
ALSO NOTED: Cancer-sniffing dog being cloned; Investment spurs Bioton shares; Genetic Chemistry wins $23M contract; Tioga touts
> The world's top cancer-sniffing canine has been cloned, and her owners are planning a pack of clones to join the hunt for canine cancer detection. Researchers have been testing dogs' ability to Read more...
ALSO NOTED: Salix gets approvable letter; Intermune drug hits the fast track; and much more...
> Should Fred Hassan (photo) give back his bonus? That's what Forbes is asking this week, saying that the Read more...
Novacea cuts staff after partner dumps collaboration
A month after Schering-Plough pulled the plug on its collaboration with Novacea for a new prostate cancer therapy--Read more...
ALSO NOTED: Washington biotech investing in growth; Merck CEO: 'I can't blame the media'; NeuroMetrix's CEO resigns; and much m
> Despite the economic slowdown, Washington state biotechs are investing hundreds of millions of dollars in new facilities. Read more...
ALSO NOTED: Dyax to close R&D facility;Nastech sells shares; and much more...
> Dyax says it plans to close its research facility in Belgium as it focuses on commercializing DX-88 to treat hereditary angioedema. Read more...
ALSO NOTED: Shire nabs orphan product; New prez at Cell Therapeutics; and much more...
> Shire has acquired arylsulfatase, an orphan enzyme replacement therapy in Phase I/II for Metachromatic Leukodystrophy, from the Danish company Zymenex. Read more...
ALSO NOTED: FDA approves Orencia; Delay on Amgen clotting drug decision; Icahn files suit for Biogen Idec papers; and much more
> The FDA has approved Bristol-Myers Squibb's Orencia for juvenile arthritis. Read more...
SPOTLIGHT: NJ to take the brunt of Schering's cuts
Fasten your seat belts, New Jersey, it's going to be a bumpy ride. Schering-Plough CEO Fred Hassan said that the budget ax will fall hardest in New Jersey as the company cuts more than $1 billion in Read more...
ALSO NOTED: Dendreon shares jump on investment deal; Iomai in pact with Merck; Foundation antes millions for MS leads; and much
> Schering-Plough has proven quick on the layoff trigger. The company announced a plan to cut costs by $1.5 billion by 2012 in the wake of the latest round of Vytorin controversy. Roughly 5,500 Read more...
| Press ReleasesPRESS RELEASE: Schering-Plough Reports Financial Results for Third Quarter of 2007 Schering-Plough Reports Financial Results for Third Quarter of 2007 Solid Performance Continues in Third Quarter of 2007; Company Prepares for Integration of Organon BioSciences KENILWORTH, N.J., Read more... PRESS RELEASE: Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disor Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder New Data From a Separate Study Also Show Minimal Effect on Heart Rhythm Changes Read more... |
Get more Schering Plough coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets